# Vertex Pharmaceuticals Incorporated – Consensus ‘buy’ rating and 7.3% Upside Potential

- Link: https://www.directorstalkinterviews.com/vertex-pharmaceuticals-incorporated-consensus-buy-rating-and-7.3-upside-potential/4121131807
- Published: 2023-11-01T14:35:34+00:00
- Author: Charlotte Edwards

**Vertex Pharmaceuticals Incorporated** which can be found using ticker (VRTX) now
have 24 market analysts covering the stock. The analyst consensus now points to 
a rating of ‘buy’. The range between the high target price and low target price 
is between $456.00 and $315.00 suggesting an average Analsyt target price of $388.67.
Given that the stocks previous close was at $362.11 this indicates there is a potential
upside of 7.3%. It’s also worth noting that there is a 50 day moving average of 
$354.95 while the 200 day moving average is $334.33. The market cap for the company
is 94.15B. The current share price for the company is: $364.79 USD

 The potential market cap would be $101,056,222,153 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 28.23, revenue per share of $36.96
and a 15.56% return on assets.

Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company
is focused on developing medicines that treat the underlying cause of cystic fibrosis(
CF). Its pipeline includes mid- and late-stage clinical programs in sickle cell 
disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease,
type 1 diabetes, and alpha-1 antitrypsin deficiency, and earlier-stage programs 
in diseases such as muscular dystrophies. Its marketed medicines are TRIKAFTA/KAFTRIO(
elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor
and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The Company
has a pipeline of investigational small molecule, cell and genetic therapies in 
other serious diseases where it has deep insight into causal human biology, including
sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type
1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.

Share on: